Qumata Group Limited 10964467 false 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is technological development of health risk profiling from fitness, activity and other health data. Digita Accounts Production Advanced 6.30.9574.0 true true true true true 10964467 2024-01-01 2024-12-31 10964467 2024-12-31 10964467 bus:Director8 2024-12-31 10964467 bus:OrdinaryShareClass1 2024-12-31 10964467 bus:OrdinaryShareClass2 2024-12-31 10964467 bus:OrdinaryShareClass3 2024-12-31 10964467 bus:OrdinaryShareClass4 2024-12-31 10964467 2 2024-12-31 10964467 core:CurrentFinancialInstruments 2024-12-31 10964467 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 10964467 core:FurnitureFittingsToolsEquipment 2024-12-31 10964467 bus:SmallEntities 2024-01-01 2024-12-31 10964467 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 10964467 bus:FilletedAccounts 2024-01-01 2024-12-31 10964467 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 10964467 bus:RegisteredOffice 2024-01-01 2024-12-31 10964467 bus:Director1 2024-01-01 2024-12-31 10964467 bus:Director4 2024-01-01 2024-12-31 10964467 bus:Director5 2024-01-01 2024-12-31 10964467 bus:Director8 2024-01-01 2024-12-31 10964467 bus:Director9 2024-01-01 2024-12-31 10964467 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 10964467 bus:OrdinaryShareClass2 2024-01-01 2024-12-31 10964467 bus:OrdinaryShareClass3 2024-01-01 2024-12-31 10964467 bus:OrdinaryShareClass4 2024-01-01 2024-12-31 10964467 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 10964467 core:FurnitureFittingsToolsEquipment 2024-01-01 2024-12-31 10964467 core:OfficeEquipment 2024-01-01 2024-12-31 10964467 core:Subsidiary1 2024-01-01 2024-12-31 10964467 core:Subsidiary1 1 2024-01-01 2024-12-31 10964467 core:Subsidiary1 countries:HongKong 2024-01-01 2024-12-31 10964467 core:Subsidiary2 2024-01-01 2024-12-31 10964467 core:Subsidiary2 1 2024-01-01 2024-12-31 10964467 core:Subsidiary2 countries:China 2024-01-01 2024-12-31 10964467 core:Subsidiary3 2024-01-01 2024-12-31 10964467 core:Subsidiary3 1 2024-01-01 2024-12-31 10964467 core:Subsidiary3 countries:Singapore 2024-01-01 2024-12-31 10964467 countries:AllCountries 2024-01-01 2024-12-31 10964467 2023-12-31 10964467 core:FurnitureFittingsToolsEquipment 2023-12-31 10964467 2023-01-01 2023-12-31 10964467 2023-12-31 10964467 bus:OrdinaryShareClass1 2023-12-31 10964467 bus:OrdinaryShareClass2 2023-12-31 10964467 bus:OrdinaryShareClass3 2023-12-31 10964467 bus:OrdinaryShareClass4 2023-12-31 10964467 2 2023-12-31 10964467 core:CurrentFinancialInstruments 2023-12-31 10964467 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 10964467 core:FurnitureFittingsToolsEquipment 2023-12-31 10964467 core:Subsidiary1 1 2023-01-01 2023-12-31 10964467 core:Subsidiary2 1 2023-01-01 2023-12-31 10964467 core:Subsidiary3 1 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 10964467

Qumata Group Limited

trading as Qumata

Unaudited Filleted Financial Statements

for the Year Ended 31 December 2024

 

Qumata Group Limited

trading as Qumata

Contents

Company Information

1

Directors' Report

2

Balance Sheet

3 to 4

Notes to the Unaudited Financial Statements

5 to 12

 

Qumata Group Limited

trading as Qumata

Company Information

Directors

LLL Schnettler

OOW Richards

B Karfunkel

AHY Leung

Registered office

5 New Street Square
London
EC4A 3TW

Accountants

Balance Accounts Limited
Chartered Certified Accountants
4 Beau Street
Bath
BA1 1QY

 

Qumata Group Limited

trading as Qumata

Directors' Report for the Year Ended 31 December 2024

The directors present their report and the financial statements for the year ended 31 December 2024.

Qumata unlocks the value of digital data for Life & Health insurers to provide an accurate picture of current and future mortality and morbidity and health risks for anyone with a smartphone. Instantaneously and without lengthy questionnaires or medical examinations.

Our API-based solution, once implemented into an insurer’s backend, allows for a new way of underwriting, making it faster, cheaper and just as accurate.
 

Directors of the company

The directors who held office during the year were as follows:

LLL Schnettler

OOW Richards

B Karfunkel

ARB Large (ceased 8 December 2024)

AHY Leung

Principal activity

The principal activity of the company is technological development of health risk profiling from fitness, activity and other health data.

Small companies provision statement

This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the Board on 27 September 2025 and signed on its behalf by:
 

.........................................
LLL Schnettler
Director

 

Qumata Group Limited

trading as Qumata

(Registration number: 10964467)
Balance Sheet as at 31 December 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

5

1,791

4,675

Current assets

 

Debtors

7

5,659,410

4,816,989

Cash at bank and in hand

 

5,616,768

7,106,321

 

11,276,178

11,923,310

Creditors: Amounts falling due within one year

8

(87,629)

(106,321)

Net current assets

 

11,188,549

11,816,989

Net assets

 

11,190,340

11,821,664

Capital and reserves

 

Called up share capital

9

4

4

Share premium reserve

19,557,347

19,556,999

Retained earnings

(8,367,011)

(7,735,339)

Shareholders' funds

 

11,190,340

11,821,664

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

 

Qumata Group Limited

trading as Qumata

(Registration number: 10964467)
Balance Sheet as at 31 December 2024

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 27 September 2025 and signed on its behalf by:
 

.........................................
LLL Schnettler
Director

 

Qumata Group Limited

trading as Qumata

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
5 New Street Square
London
EC4A 3TW
United Kingdom

These financial statements were authorised for issue by the Board on 27 September 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

The group provides digital health profiling and insurance risk assessments as a service to insurance companies. Revenue is recognised when the services are provided on a straight line basis over the life of the contract. Where revenue is received for one-off non refundable purposes such as set up of a new project and a proof of concept, revenue is recognised upon invoicing due to the short term nature of this type of work.

Revenue comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Revenue is shown net of sales/value added tax, returns, rebates and discounts.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

 

Qumata Group Limited

trading as Qumata

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Taxation

The tax credit for the period comprises the Group’s current and deferred taxation charges. As the Company does not have taxable profits for the period this is Nil. The company is eligible for Research & Development tax relief awarded by the UK Government. The amounts eligible and refunded are included in Other debtors (Note 7).

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses. The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Furniture, fittings and equipment are considered to be capitalised as fixed assets for items costing more than £1,000 per item. Items with lower value are accounted for in expenses.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Office equipment

Straight line over 3 years

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

 

Qumata Group Limited

trading as Qumata

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Cash and cash equivalents

Cash and cash equivalents reflect cash held in bank accounts under the company’s name. The company does not hold other cash equivalents.

Trade debtors

Trade debtors are amounts due from customers for services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expenses when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Share based payments

The company operates an equity-settled, share-based compensation plan, under which the entity receives services from employees as consideration for equity instruments (options) of the entity. The fair value of the employee services received is measured by reference to the estimated fair value at the grant date of equity instruments granted and is recognised as an expense over the vesting period. The estimated fair value of the option granted is calculated using the Black Scholes option pricing model. The total amount expensed is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied.

The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are exercised.

 

Qumata Group Limited

trading as Qumata

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 8 (2023 - 12).

 

Qumata Group Limited

trading as Qumata

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

4

Loss before tax

Arrived at after charging/(crediting)

2024
£

2023
£

Depreciation expense

4,137

6,236

5

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 January 2024

17,928

17,928

Additions

1,253

1,253

At 31 December 2024

19,181

19,181

Depreciation

At 1 January 2024

13,253

13,253

Charge for the year

4,137

4,137

At 31 December 2024

17,390

17,390

Carrying amount

At 31 December 2024

1,791

1,791

At 31 December 2023

4,675

4,675

 

Qumata Group Limited

trading as Qumata

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

6

Investments

Details of undertakings

Details of the investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking

Registered office

Holding

Proportion of voting rights and shares held

2024

2023

Subsidiary undertakings

Qumata Asia Limited (formerly HealthyHealth Asia Limited)

Unit 1603, 16/F, The L. Plaza,
367 - 375 Queen's Road Central,
Sheung Wan,
Hong Kong

Hong Kong

Ordinary

100%

100%

Shanghai Qumata Information Technology Co., Ltd

Building 1, No 5500 Yuanjiang Road
Minhang District
Shanghai

China

Ordinary

100%

100%

Qumata Asiapac Pte. Ltd

68 Circular Road
#02-01
Singapore (049422)

Singapore

Ordinary

100%

100%

The group qualifies as a small group in the period and under the Companies Act 2006 it is not required to prepare consolidated accounts. The company has chosen to apply this exemption.

 

Qumata Group Limited

trading as Qumata

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

7

Debtors

Note

2024
£

2023
£

Trade debtors

 

-

19,637

Amounts owed by related parties

3,712,041

3,162,468

Other debtors

 

10,974

222,076

Prepayments

 

123,634

25,573

Deferred tax assets

1,755,016

1,168,900

Income tax asset

57,745

218,335

 

5,659,410

4,816,989

8

Creditors

Creditors: amounts falling due within one year

Note

2024
£

2023
£

Due within one year

 

Trade creditors

 

6,938

12,989

Amounts due to related parties

-

37,136

Social security and other taxes

 

17,457

-

Outstanding defined contribution pension costs

 

1,101

1,136

Other payables

 

9,924

11,288

Accruals

 

33,333

24,210

Deferred Income

 

18,876

19,562

 

87,629

106,321

 

Qumata Group Limited

trading as Qumata

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

9

Share capital

Allotted, called up and fully paid shares

 

2024

2023

 

No.

£

No.

£

Ordinary of £0.000001 each

2,009,892

2.01

1,975,125

1.98

Series A Ordinary Shares of £0.000001 each

1,268,855

1.27

1,268,855

1.27

Series A1A Ordinary Shares of £0.000001 each

417,460

0.42

417,460

0.42

Series A1B Ordinary Shares of £0.000001 each

400,111

0.40

400,111

0.40

 

4,096,318

4

4,061,551

4